Search Results - "Carlino, M"

Seismic anisotropy to investigate lithospheric-scale tectonic structures and mantle dynamics in southern Italy by Scarfì, L., Firetto Carlino, M., Musumeci, C.

“…Subduction zones may be characterised by deep-seated tectonic structures whose effects propagate to the upper plate through faulting and magmatism. The overall…”
Get full text

Crustal Structure of Etna Volcano (Italy) From P‐Wave Anisotropic Tomography by Lo Bue, R., Rappisi, F., Firetto Carlino, M., Giampiccolo, E., Cocina, O., Vanderbeek, B. P., Faccenda, M.

“…Several seismic tomographic studies have been carried out to outline the intricate interplay between tectonics and magma uprising at Etna volcano. Most of…”
Get full text

Time and space scattered volcanism of Mt. Etna driven by strike-slip tectonics by Firetto Carlino, M., Cavallaro, D., Coltelli, M., Cocchi, L., Zgur, F., Patanè, D.

“…High-resolution seismic reflection, magnetic and gravity data, acquired offshore of Etna volcano, provide a new insight to understanding the relationship…”
Get full text

Plant growth-promoting rhizobacteria inoculation and nitrogen fertilization increase maize (Zea mays L.) grain yield and modified rhizosphere microbial communities by Di Salvo, Luciana P., Cellucci, Gabriel C., Carlino, M. Eugenia, García de Salamone, Inés E.

Get full text

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma by Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.

“…Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating…”
Get full text

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab by Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., McQuade, J.L., Shoushtari, A.N., Tsai, K.K., Eroglu, Z., Klein, O., Hassel, J.C., Sosman, J.A., Guminski, A., Sullivan, R.J., Ribas, A., Carlino, M.S., Davies, M.A., Sandhu, S.K., Long, G.V.

“…Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting…”
Get full text

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma by Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., Kapiteijn, E.

“…Background Up to 50% of patients with uveal melanoma develop metastases (MUM) with a poor prognosis and median overall survival of approximately 1 year…”
Get full text

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma by Tan, A.C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M.S., Guminski, A.D., Long, G.V., Menzies, A.M.

“…Immune checkpoint inhibitor therapy has resulted in impressive and durable clinical activity for many cancers including melanoma; however, there remain few…”
Get full text

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy by Owen, C.N., Shoushtari, A.N., Chauhan, D., Palmieri, D.J., Lee, B., Rohaan, M.W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M.A., Millward, M., Patel, S.P., Haydon, A., Johnson, D.B., Lo, S., Blank, C.U., Sandhu, S., Carlino, M.S., Larkin, J.M.G., Menzies, A.M., Long, G.V.

“…Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%–30% of…”
Get full text

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma by Carlino, M S, Haydu, L E, Kakavand, H, Menzies, A M, Hamilton, A L, Yu, B, Ng, C C, Cooper, W A, Thompson, J F, Kefford, R F, O'Toole, S A, Scolyer, R A, Long, G V

“…Background: The prognostic significance of BRAF and NRAS mutations in metastatic melanoma patients remains uncertain, with several studies reporting…”
Get full text

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients by Lee, J.H., Saw, R.P., Thompson, J.F., Lo, S., Spillane, A.J., Shannon, K.F., Stretch, J.R., Howle, J., Menzies, A.M., Carlino, M.S., Kefford, R.F., Long, G.V., Scolyer, R.A., Rizos, H.

“…The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of…”
Get full text

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma by Owen, C.N., Bai, X., Quah, T., Lo, S.N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I.L.M., Thompson, N., Vanella, V., Gerard, C.L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C.U., Welsh, S.J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J.L., Ascierto, P.A., Zimmer, L., Johnson, D.B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M.S., Sullivan, R.J., Long, G.V., Menzies, A.M.

“…Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ±…”
Get full text

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy by Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O

“…Background: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4…”
Get full text

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia by Cass, S.H., Tobin, J.W.D., Seo, Y.D., Gener-Ricos, G., Keung, E.Z., Burton, E.M., Davies, M.A., McQuade, J.L., Lazar, A.J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A.M., Carlino, M., Smith, J.L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S.A., Markovic, S.N., Ding, W., Call, T.G., Hampel, P.J., Long, G.V., Wargo, J.A., Ferrajoli, A.

“…Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been…”
Get full text

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma by Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., Carlino, M. S., Hong, A., Long, G. V.

“…The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and…”
Get full text

FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma by Dimitriou, F., Lo, S.N., Tan, A.C., Emmett, L., Kapoor, R., Carlino, M.S., Long, G.V., Menzies, A.M.

“…We have previously shown that 75% of patients treated with programmed cell death protein 1 (PD-1) with or without CTLA4 who have not progressed by 1 year have…”
Get full text

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study by Dimitriou, F., Namikawa, K., Reijers, I.L.M., Buchbinder, E.I., Soon, J.A., Zaremba, A., Teterycz, P., Mooradian, M.J., Armstrong, E., Nakamura, Y., Vitale, M.G., Tran, L.E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K.C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C.J., Zaman, F., Haydon, A., Carvajal, R.D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M.S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D.B., Ascierto, P.A., Shoushtari, A.N., Sullivan, R.J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C.U., Lo, S.N., Menzies, A.M., Long, G.V.

“…BACKGROUNDMucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors…”
Get full text

Quantitative analysis and virulence phenotypes of atypical enteropathogenic Escherichia coli (EPEC) acquired from diarrheal stool samples from a Midwest US hospital by Carlino, MJ, Kralicek, SE, Santiago, SA, Sitaraman, LM, Harrington, AT, Hecht, Gail A.

“…Infectious diarrhea causes approximately 179 million illnesses annually in the US. Multiplex PCR assays for enteric pathogens detect enteropathogenic…”
Get full text

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 by Long, G.V., Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., Schachter, J., Grob, J.-J., Lotem, M., Middleton, M.R., Neyns, B., Steven, N., Ribas, A., Walpole, E., Carlino, M.S., Lebbe, C., Sznol, M., Jensen, E., Leiby, M.A., Ibrahim, N., Robert, C.

“…Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. In the…”
Get full text

Is chemotherapy still an option in the treatment of melanoma? by Carlino, M.S., Long, G.V.

Get full text